The latest update is out from TransCode Therapeutics ( (RNAZ) ).
On May 5, 2025, TransCode Therapeutics announced a 1-for-28 reverse stock split of its common stock, effective May 15, 2025, to meet Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares from 23,341,336 to approximately 833,620, with no fractional shares issued, and aims to maintain the company’s listing on the Nasdaq Capital Market.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics. Utilizing its proprietary TTX nanoparticle platform, the company aims to defeat cancer by targeting metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis, and is developing a portfolio of RNA therapeutic candidates to address various genetic targets in cancer treatment.
YTD Price Performance: -85.50%
Average Trading Volume: 9,388,972
Technical Sentiment Signal: Buy
Current Market Cap: $11.96M
Learn more about RNAZ stock on TipRanks’ Stock Analysis page.